Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 225

1.

Cross-neutralization of 1918 and 2009 influenza viruses: role of glycans in viral evolution and vaccine design.

Wei CJ, Boyington JC, Dai K, Houser KV, Pearce MB, Kong WP, Yang ZY, Tumpey TM, Nabel GJ.

Sci Transl Med. 2010 Mar 24;2(24):24ra21. doi: 10.1126/scitranslmed.3000799.

2.

A Bivalent Heterologous DNA Virus-Like-Particle Prime-Boost Vaccine Elicits Broad Protection against both Group 1 and 2 Influenza A Viruses.

Jiang W, Wang S, Chen H, Ren H, Huang X, Wang G, Chen Z, Chen L, Chen Z, Zhou P.

J Virol. 2017 Apr 13;91(9). pii: e02052-16. doi: 10.1128/JVI.02052-16. Print 2017 May 1.

PMID:
28179535
3.

Induction of broadly neutralizing H1N1 influenza antibodies by vaccination.

Wei CJ, Boyington JC, McTamney PM, Kong WP, Pearce MB, Xu L, Andersen H, Rao S, Tumpey TM, Yang ZY, Nabel GJ.

Science. 2010 Aug 27;329(5995):1060-4. doi: 10.1126/science.1192517. Epub 2010 Jul 15.

4.

Pre-existing immunity with high neutralizing activity to 2009 pandemic H1N1 influenza virus in Shanghai population.

Liu X, Liu Y, Zhang Y, Chen Z, Tang Z, Xu Q, Wang Y, Zhao P, Qi Z.

PLoS One. 2013;8(3):e58810. doi: 10.1371/journal.pone.0058810. Epub 2013 Mar 19.

5.

Addition of N-glycosylation sites on the globular head of the H5 hemagglutinin induces the escape of highly pathogenic avian influenza A H5N1 viruses from vaccine-induced immunity.

Hervé PL, Lorin V, Jouvion G, Da Costa B, Escriou N.

Virology. 2015 Dec;486:134-45. doi: 10.1016/j.virol.2015.08.033. Epub 2015 Oct 1.

6.

A VLP vaccine induces broad-spectrum cross-protective antibody immunity against H5N1 and H1N1 subtypes of influenza A virus.

Wu CY, Yeh YC, Chan JT, Yang YC, Yang JR, Liu MT, Wu HS, Hsiao PW.

PLoS One. 2012;7(8):e42363. doi: 10.1371/journal.pone.0042363. Epub 2012 Aug 7.

7.

Pandemic H1N1 influenza vaccine induces a recall response in humans that favors broadly cross-reactive memory B cells.

Li GM, Chiu C, Wrammert J, McCausland M, Andrews SF, Zheng NY, Lee JH, Huang M, Qu X, Edupuganti S, Mulligan M, Das SR, Yewdell JW, Mehta AK, Wilson PC, Ahmed R.

Proc Natl Acad Sci U S A. 2012 Jun 5;109(23):9047-52. doi: 10.1073/pnas.1118979109. Epub 2012 May 21.

8.

Structural basis of preexisting immunity to the 2009 H1N1 pandemic influenza virus.

Xu R, Ekiert DC, Krause JC, Hai R, Crowe JE Jr, Wilson IA.

Science. 2010 Apr 16;328(5976):357-60. doi: 10.1126/science.1186430. Epub 2010 Mar 25.

9.

[Monoclonal antibodies with high virus-neutralizing activity against pandemic influenza virus A/llV-Moscow/01/2009 (H1N1)swl].

Klimova RR, Masalova OV, Burtseva EI, Chichev EV, Lesnova EI, Oskerko TA, Mukasheva EA, Rudneva IA, Lvov DK, Kushch AA.

Vopr Virusol. 2011 May-Jun;56(3):15-20. Russian.

PMID:
21786621
10.

Neutralization and Binding Profile of Monoclonal Antibodies Generated Against Influenza A H1N1 Viruses.

Shembekar N, Mallajosyula VV, Malik A, Saini A, Varadarajan R, Gupta SK.

Monoclon Antib Immunodiagn Immunother. 2016 Aug;35(4):191-8. doi: 10.1089/mab.2016.0015. Epub 2016 Jul 27.

PMID:
27463230
11.

Synthetic Toll-like receptor 4 (TLR4) and TLR7 ligands as influenza virus vaccine adjuvants induce rapid, sustained, and broadly protective responses.

Goff PH, Hayashi T, Martínez-Gil L, Corr M, Crain B, Yao S, Cottam HB, Chan M, Ramos I, Eggink D, Heshmati M, Krammer F, Messer K, Pu M, Fernandez-Sesma A, Palese P, Carson DA.

J Virol. 2015 Mar;89(6):3221-35. doi: 10.1128/JVI.03337-14. Epub 2015 Jan 7.

12.

Neutralizing and protective epitopes of the 2009 pandemic influenza H1N1 hemagglutinin.

Schmeisser F, Friedman R, Besho J, Lugovtsev V, Soto J, Wang W, Weiss C, Williams O, Xie H, Ye Z, Weir JP.

Influenza Other Respir Viruses. 2013 May;7(3):480-90. doi: 10.1111/irv.12029. Epub 2012 Nov 5.

13.

Immunization with 1976 swine H1N1- or 2009 pandemic H1N1-inactivated vaccines protects mice from a lethal 1918 influenza infection.

Easterbrook JD, Kash JC, Sheng ZM, Qi L, Gao J, Kilbourne ED, Eichelberger MC, Taubenberger JK.

Influenza Other Respir Viruses. 2011 May;5(3):198-205. doi: 10.1111/j.1750-2659.2010.00191.x. Epub 2011 Jan 25.

14.

Glycosylations in the globular head of the hemagglutinin protein modulate the virulence and antigenic properties of the H1N1 influenza viruses.

Medina RA, Stertz S, Manicassamy B, Zimmermann P, Sun X, Albrecht RA, Uusi-Kerttula H, Zagordi O, Belshe RB, Frey SE, Tumpey TM, García-Sastre A.

Sci Transl Med. 2013 May 29;5(187):187ra70. doi: 10.1126/scitranslmed.3005996.

15.

A human monoclonal antibody derived from a vaccinated volunteer recognizes heterosubtypically a novel epitope on the hemagglutinin globular head of H1 and H9 influenza A viruses.

Boonsathorn N, Panthong S, Koksunan S, Chittaganpitch M, Phuygun S, Waicharoen S, Prachasupap A, Sasaki T, Kubota-Koketsu R, Yasugi M, Ono K, Arai Y, Kurosu T, Sawanpanyalert P, Ikuta K, Watanabe Y.

Biochem Biophys Res Commun. 2014 Sep 26;452(3):865-70. doi: 10.1016/j.bbrc.2014.09.008. Epub 2014 Sep 6.

PMID:
25204499
16.

Modified vaccinia virus Ankara expressing the hemagglutinin of pandemic (H1N1) 2009 virus induces cross-protective immunity against Eurasian 'avian-like' H1N1 swine viruses in mice.

Castrucci MR, Facchini M, Di Mario G, Garulli B, Sciaraffia E, Meola M, Fabiani C, De Marco MA, Cordioli P, Siccardi A, Kawaoka Y, Donatelli I.

Influenza Other Respir Viruses. 2014 May;8(3):367-75. doi: 10.1111/irv.12221. Epub 2013 Dec 23.

17.

Neutralizing antibodies derived from the B cells of 1918 influenza pandemic survivors.

Yu X, Tsibane T, McGraw PA, House FS, Keefer CJ, Hicar MD, Tumpey TM, Pappas C, Perrone LA, Martinez O, Stevens J, Wilson IA, Aguilar PV, Altschuler EL, Basler CF, Crowe JE Jr.

Nature. 2008 Sep 25;455(7212):532-6. doi: 10.1038/nature07231. Epub 2008 Aug 17. Erratum in: Nature. 2012 Oct 25;490(7421):570.

18.

Seasonal H1N1 2007 influenza virus infection is associated with elevated pre-exposure antibody titers to the 2009 pandemic influenza A (H1N1) virus.

Lemaitre M, Leruez-Ville M, De Lamballerie XN, Salez N, Garrone P, Fluckiger AC, Klatzmann D, Carrat F.

Clin Microbiol Infect. 2011 May;17(5):732-7. doi: 10.1111/j.1469-0691.2010.03352.x. Epub 2010 Oct 29.

19.

Fully human broadly neutralizing monoclonal antibodies against influenza A viruses generated from the memory B cells of a 2009 pandemic H1N1 influenza vaccine recipient.

Hu W, Chen A, Miao Y, Xia S, Ling Z, Xu K, Wang T, Xu Y, Cui J, Wu H, Hu G, Tian L, Wang L, Shu Y, Ma X, Xu B, Zhang J, Lin X, Bian C, Sun B.

Virology. 2013 Jan 20;435(2):320-8. doi: 10.1016/j.virol.2012.09.034. Epub 2012 Oct 16.

20.

A human antibody recognizing a conserved epitope of H5 hemagglutinin broadly neutralizes highly pathogenic avian influenza H5N1 viruses.

Hu H, Voss J, Zhang G, Buchy P, Zuo T, Wang L, Wang F, Zhou F, Wang G, Tsai C, Calder L, Gamblin SJ, Zhang L, Deubel V, Zhou B, Skehel JJ, Zhou P.

J Virol. 2012 Mar;86(6):2978-89. doi: 10.1128/JVI.06665-11. Epub 2012 Jan 11.

Supplemental Content

Support Center